Mirum to share Phase 3 AZURE-1 brelovitug topline data in chronic hepatitis delta on Sept. 28 investor call
MIRM•Mirum Pharmaceuticals scheduled a Sept. 28, 2026, investor call to release topline Phase 3 AZURE-1 results for brelovitug in chronic hepatitis delta, along with 48-week data from the study’s Phase 2b portion.
1. Investor call scheduled
Mirum Pharmaceuticals scheduled an investor call for Sept. 28, 2026, to release topline Phase 3 AZURE-1 results for brelovitug in chronic hepatitis delta. The event will also include 48-week data from the study’s Phase 2b portion; the results have not yet been presented.
